If You Want to Beat the Market, Start With These 3 Stocks

The article highlights three market-resilient names—Eli Lilly, Chevron, and Alphabet—each posting strong operating trends and constructive outlooks. Eli Lilly reported Q1 revenue of $19.8B, up 56%, with EPS up 170% to $8.26 and raised full-year guidance; Chevron beat EPS at $1.41, produced 3.9 million barrels/day, and yields 3.73% after 38 straight years of dividend increases; Alphabet grew revenue 22% to $109.9B and Google Cloud revenue 63% to $20B. Overall tone is bullish on defensive, high-quality stocks that can outperform amid market volatility.

Analysis

This setup is less about “defensiveness” in the traditional sense and more about owning the three best cash-flow compounding machines in three very different regimes. LLY and GOOGL are the higher-duration growth winners if rates drift lower or stabilize, while CVX is the convex hedge if geopolitics keeps keeping a floor under commodity prices; that combination makes the basket unusually robust to macro regime shifts. The second-order point: these names are also absorbing incremental capital that would otherwise rotate into lower-quality cyclicals, which can widen dispersion across sectors and keep index-level volatility elevated even if the headline market grinds higher.

The market may be underestimating the path dependency of each name. LLY’s biggest risk is not demand but execution: any manufacturing or labeling setback on obesity assets could compress the premium quickly because the stock already discounts sustained category dominance; near term, this is a sentiment-driven name with event risk over the next 1-2 quarters. CVX’s upside is tied more to capital discipline than oil beta at this point—if management converts structural cost reductions into buybacks rather than chasing volume, the stock can rerate; if crude fades, the dividend still cushions but multiple expansion stalls.

GOOGL is the most interesting from a contrarian standpoint because consensus still treats AI spend as a margin headwind rather than a moat-building exercise. If capex is depressing near-term free cash flow but locking in cloud backlog and search retention, the market may be too slow to credit the installed-base advantage; that argues for buying weakness rather than chasing strength. The risk is that capex intensity stays elevated into 2027 without a commensurate reacceleration in monetization, which would cap upside for several quarters despite strong top-line momentum.

Key Decisions for Investors

• Long LLY on any 3-5% pullback over the next 2-4 weeks; treat as a quality-growth hedge with 12-month upside if obesity/trials continue to de-risk, but trim if the stock re-rates more than ~20% above the market on no new data.
• Buy CVX as a 6-9 month carry trade versus high-beta energy equities; dividend and buyback support create a better downside profile than E&P names if crude retraces, while still participating if geopolitics keeps prices firm.
• Initiate a long GOOGL / short XLC basket or outright long GOOGL on post-capex weakness; target 6-12 months, with the thesis that AI spend monetization inflects before consensus models it.
• Pair trade: long LLY vs short a basket of lower-quality healthcare or specialty pharma laggards; the market is likely to keep rewarding pipeline certainty and scale, while weaker balance sheets face multiple compression in a risk-off tape.
• Consider GOOGL call spreads 6-9 months out to express upside with defined risk; best entry is after any capex-related drawdown, not on a breakout, since the stock’s valuation already embeds a fair amount of optimism.